膽囊癌外科治療的思考與進展_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 姜小清 , 馮飛靈

海軍軍醫大學膽道腫瘤專病中心東方肝膽外科醫院膽道一科（上海 ?200438）;

Corresponding?author：

姜小清, Email: jxq1225@sina.com

Keywords：

DOI：

10.7507/1007-9424.201903022

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 姜小清, 馮飛靈. 膽囊癌外科治療的思考與進展. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(3): 257-260. doi: 10.7507/1007-9424.201903022 Copy

1.	Chen W, Zheng R, Baade P, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2.	Misra S, Chaturvedi A, Misra NC, et al. Carcinoma of the gallbladder. Lancet Oncol, 2003, 4(3): 167-176.
3.	Zhu AX, Hong TS, Hezel AF, et al. Current management of gallbladder carcinoma. Oncologist, 2010, 15(2): 168-181.
4.	Raki? M, Patrlj L, Kopljar M, et al. Gallbladder cancer. Hepatobiliary Surg Nutr, 2014, 3(5): 221-226.
5.	Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase Ⅱ trial. J Clin Oncol, 2005, 23(10): 2332-2338.
6.	Kim ST, Park JO, Lee J, et al. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer, 2006, 106(6): 1339-1346.
7.	André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol, 2004, 15(9): 1339-1343.
8.	Shih SP, Schulick RD, Cameron JL, et al. Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg, 2007, 245(6): 893-901.
9.	Chang J, Jang JY, Lee KB, et al. Improvement of clinicaloutcomes in the patients with gallbladder cancer: lessons from periodic comparison in a tertiary referral center. J Hepatobiliary Pancreat Sci, 2016, 23: 234-241.
10.	Chijiiwa K, Torisu M. Primary carcinoma of the cystic duct. J Clin Gastroenterol, 1993, 16: 309-313.
11.	Farrar DA. Carcinoma of the cystic duct. Br J Surg, 1951, 39: 183-185.
12.	Yokoyama Y, Nishio H, Ebata T, et al. New classification of cystic duct carcinoma. World J Surg, 2008, 32(4): 621-626.
13.	Kondo S, Nimura Y, Kamiya J, et al. Mode of tumor spread and surgical strategy in gallbladder carcinoma. Langenbecks Arch Surg, 2002, 387(5-6): 222-228.
14.	Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg, 2015, 261(4): 733-739.
15.	Cho JK, Lee W, Jang JY, et al. Validation of the oncologic effect of hepatic resection for T2 gallbladder cancer: a retrospective study. World J Surg Oncol, 2019, 17(1): 8.
16.	Lee H, Choi DW, Park JY, et al. Surgical strategy for T2 gallbladder cancer according to tumor location. Ann Surg Oncol, 2015, 22(8): 2779-2786.
17.	Park TJ, Ahn KS, Kim YH, et al. The optimal surgical resection approach for T2 gallbladder carcinoma: evaluating the role of surgical extent according to the tumor location. Ann Surg Treat Res, 2018, 94(3): 135-141.
18.	夏春芳, 潘友蘭, 黎靜, 等. 奧沙利鉑為主的靜脈化療聯合腹腔溫熱灌注和體外高頻透熱治療晚期大腸癌的臨床觀察. 中國現代醫學雜志, 2010, 20(9): 1420-1422.
19.	K?nigsrainer I. Selection criteria for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol, 2011, 17(37): 4153-4156.
20.	Cui S, Ba M, Tang Y, et al. B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites. Oncol Rep, 2012, 28(4): 1325-1331.
21.	Amblard l, Mercier F, Bartlett DL, et al. Cytoreductive surgery and HIPEC improve Survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIGRENAPE groups. Eur J Surg Oncol, 2018, 44(9): 1378-1383.
22.	于建全, 馮飛靈, 沈洋, 等. 持續腹腔熱灌注化療治療進展期膽管癌的臨床療效觀察. 第二軍醫大學學報, 2017, 38(5): 570-575.
23.	Shirai Y, Sakata J, Wakai T, et al. " Extended” radical cholecystectomy for gallbladder cancer: long-term outcomes, indications and limitations. World J Gastroenterol, 2012, 18(34): 4736-4743.
24.	Miwa S, Kobayashi A, Akahane Y, et a1. Is major hepatectomy with pancreatoduodenectomy justified for advanced biliary malignancy. J Hepatobiliary Pancreat Surg, 2007, 14(2): 136-141.
25.	Sternby Eilard M, Lundgren L, Cahlin C, et al. Surgicaltreatment for gallbladder cancer - a systematic literature review. Scand J Gastroenterol, 2017, 52(5): 505-514.
26.	Kurahara H, Maemura K, Mataki Y, et al. Indication of extrahepatic bile duct resection for gallbladder cancer. Langenbecks Arch Surg, 2018, 403(1): 45-51.
27.	Yang XW, Yuan JM, Chen JY, et al. The prognostic importance of jaundice in surgical resection with curative intent for gallbladdercancer. BMC Cancer, 2014, 14: 652.

1. Chen W, Zheng R, Baade P, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2. Misra S, Chaturvedi A, Misra NC, et al. Carcinoma of the gallbladder. Lancet Oncol, 2003, 4(3): 167-176.
3. Zhu AX, Hong TS, Hezel AF, et al. Current management of gallbladder carcinoma. Oncologist, 2010, 15(2): 168-181.
4. Raki? M, Patrlj L, Kopljar M, et al. Gallbladder cancer. Hepatobiliary Surg Nutr, 2014, 3(5): 221-226.
5. Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase Ⅱ trial. J Clin Oncol, 2005, 23(10): 2332-2338.
6. Kim ST, Park JO, Lee J, et al. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer, 2006, 106(6): 1339-1346.
7. André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol, 2004, 15(9): 1339-1343.
8. Shih SP, Schulick RD, Cameron JL, et al. Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg, 2007, 245(6): 893-901.
9. Chang J, Jang JY, Lee KB, et al. Improvement of clinicaloutcomes in the patients with gallbladder cancer: lessons from periodic comparison in a tertiary referral center. J Hepatobiliary Pancreat Sci, 2016, 23: 234-241.
10. Chijiiwa K, Torisu M. Primary carcinoma of the cystic duct. J Clin Gastroenterol, 1993, 16: 309-313.
11. Farrar DA. Carcinoma of the cystic duct. Br J Surg, 1951, 39: 183-185.
12. Yokoyama Y, Nishio H, Ebata T, et al. New classification of cystic duct carcinoma. World J Surg, 2008, 32(4): 621-626.
13. Kondo S, Nimura Y, Kamiya J, et al. Mode of tumor spread and surgical strategy in gallbladder carcinoma. Langenbecks Arch Surg, 2002, 387(5-6): 222-228.
14. Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg, 2015, 261(4): 733-739.
15. Cho JK, Lee W, Jang JY, et al. Validation of the oncologic effect of hepatic resection for T2 gallbladder cancer: a retrospective study. World J Surg Oncol, 2019, 17(1): 8.
16. Lee H, Choi DW, Park JY, et al. Surgical strategy for T2 gallbladder cancer according to tumor location. Ann Surg Oncol, 2015, 22(8): 2779-2786.
17. Park TJ, Ahn KS, Kim YH, et al. The optimal surgical resection approach for T2 gallbladder carcinoma: evaluating the role of surgical extent according to the tumor location. Ann Surg Treat Res, 2018, 94(3): 135-141.
18. 夏春芳, 潘友蘭, 黎靜, 等. 奧沙利鉑為主的靜脈化療聯合腹腔溫熱灌注和體外高頻透熱治療晚期大腸癌的臨床觀察. 中國現代醫學雜志, 2010, 20(9): 1420-1422.
19. K?nigsrainer I. Selection criteria for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol, 2011, 17(37): 4153-4156.
20. Cui S, Ba M, Tang Y, et al. B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites. Oncol Rep, 2012, 28(4): 1325-1331.
21. Amblard l, Mercier F, Bartlett DL, et al. Cytoreductive surgery and HIPEC improve Survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIGRENAPE groups. Eur J Surg Oncol, 2018, 44(9): 1378-1383.
22. 于建全, 馮飛靈, 沈洋, 等. 持續腹腔熱灌注化療治療進展期膽管癌的臨床療效觀察. 第二軍醫大學學報, 2017, 38(5): 570-575.
23. Shirai Y, Sakata J, Wakai T, et al. " Extended” radical cholecystectomy for gallbladder cancer: long-term outcomes, indications and limitations. World J Gastroenterol, 2012, 18(34): 4736-4743.
24. Miwa S, Kobayashi A, Akahane Y, et a1. Is major hepatectomy with pancreatoduodenectomy justified for advanced biliary malignancy. J Hepatobiliary Pancreat Surg, 2007, 14(2): 136-141.
25. Sternby Eilard M, Lundgren L, Cahlin C, et al. Surgicaltreatment for gallbladder cancer - a systematic literature review. Scand J Gastroenterol, 2017, 52(5): 505-514.
26. Kurahara H, Maemura K, Mataki Y, et al. Indication of extrahepatic bile duct resection for gallbladder cancer. Langenbecks Arch Surg, 2018, 403(1): 45-51.
27. Yang XW, Yuan JM, Chen JY, et al. The prognostic importance of jaundice in surgical resection with curative intent for gallbladdercancer. BMC Cancer, 2014, 14: 652.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

膽囊癌外科治療的思考與進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content